An Study of Aripiprazole in the Treatment of Methamphetamine Dependence

Wei Hao

Status and phase: Terminated; Phase 4

Conditions: Methamphetamine Dependence

Treatments: Drug: Aripiprazole; Drug: placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT01813656

100000-068942

Details and patient eligibility

About

Methamphetamine substance use is common worldwide. No approved pharmacologic treatments for methamphetamine dependence exist. Aripiprazole are Second generation antipsychotics，but have different pharmacological effects of neurotransmitters.To determine whether mirtazapine would reduce methamphetamine use among mehtamphetamine addicts.

Full description

Methods:A Multiple-Center, Randomized, Double-Blind.

Enrollment: 10 patients

Sex: All

Ages: 19 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients,Diagnostic and Statistical Manual of Mental Disorders 4thed. (DSM-IV) criteria for Methamphetamine dependence.
2. Must sign a Information consent form.
3. Required to provide detailed address and phone number

Exclusion criteria

1. Serious organic disease.
2. Suicide ideation or hurt others.
3. Taking antipsychotic within two weeks before.
4. drug allergy to Risperidone or Aripiprazole.
5. pregnancy and breastfeeding women.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

10 participants in 2 patient groups, including a placebo group

Aripiprazole

Experimental group

Description:

Aripiprazole arm,5mg/pill,10mg/day.last12weeks.

Treatment:

Drug: Aripiprazole

Sugar pill

Placebo Comparator group

Description:

placebo arm,5mg/pill,10mg/day,last12weeks

Treatment:

Drug: placebo